re: the unloved sector - biotech, page-5

re: the unloved sector - biotech Apparently CSL have put together a team looking at buying into early stage antibody sector its obvious AAH would be on the radar as they fit the criteria perfectly are home grown and cashed up interesting times for this over the next 3 months CSL have the potential to get a good slice of this market if they play their cards right and good old AAH holders get shafted.

If the other deal CSL have got going falls over its probably very likely something could eventuate however they are still on the prowl regardless.